Browse the corpus

DiGeorge syndrome, now understood within the broader 22q11.2 deletion syndrome spectrum, encompasses a wide range of congenital, immunologic, developmental, and psychiatric manifestations resulting from disrupted pharyngeal arch development. This course reviews the highly variable presentations of DiGeorge syndrome that include cardiac malformations, thymic hypoplasia, hypocalcemia, palatal abnormalities, learning disabilities, and a markedly elevated risk of schizophrenia spectrum disorders. Diagnostic confirmation which relies on chromosomal microarray, with additional immunologic, cardiac, endocrine, developmental, and psychiatric evaluations guiding long-term management as well as early recognition through newborn screening is also discussed. This activity outlines the genetic basis, phenotypic variability, diagnostic evaluation, and evidence-based management of 22q11.2 deletion syndrome. Participants gain enhanced ability to recognize diverse clinical presentations, interpret immunologic and genetic data, and coordinate comprehensive care across specialties. This activity for healthcare professionals is designed to enhance the learner's competence in identifying DiGeorge syndrome, individualized treatment planning, vaccination decision-making, chronic disease monitoring, patient-centered counseling, and implementing an appropriate interprofessional approach, including mental health risk assessment and genetic counseling principles, when managing this condition essential for imroving patient outcomes and quality of life. Objectives: Evaluate patients presenting with suggestive clinical features  of DiGeorge syndrome using current diagnostic criteria. Implement evidence-based management strategies for complete DiGeorge syndrome. Differentiate between the phenotypes of DiGeorge syndrome to determine appropriate interventions. Coordinate interprofessional care among team members to address the comprehensive needs of patients with DiGeorge syndrome. Access free multiple choice questions on this topic.

DiGeorge Syndrome, now recognized as part of the 22q11.2 deletion syndrome spectrum, represents a multisystem disorder resulting from defects in the development of structures derived from the pharyngeal arches during embryogenesis. First comprehensively described by Dr. Angelo DiGeorge in 1965, the condition classically presents with immunodeficiency, hypoparathyroidism, and congenital heart disease.[1] The syndrome encompasses what were historically described as separate entities including velocardiofacial syndrome, Shprintzen syndrome, and conotruncal anomaly face syndrome, all now understood to share the common genetic etiology of 22q11.2 deletion. Current nomenclature recommends using "22q11.2 deletion syndrome" when the genetic deletion is confirmed, while "DiGeorge syndrome" is reserved for individuals with the clinical phenotype but without an identified deletion.[2][3] The clinical spectrum extends beyond the classic triad to include palatal abnormalities, renal anomalies, gastrointestinal manifestations, skeletal defects, developmental delay, learning disabilities, and a significantly elevated risk of psychiatric disorders, particularly schizophrenia spectrum disorders. The variable expressivity and incomplete penetrance create diagnostic challenges, with some individuals remaining undiagnosed until adulthood when psychiatric symptoms emerge.[4] Perhaps the most clinically significant feature is thymic hypoplasia or aplasia, which determines the degree of T-cell immunodeficiency.[5] Complete DiGeorge syndrome, characterized by complete absence of thymic tissue and profound T-cell lymphopenia, affects less than 1% of individuals with 22q11.2 deletion but represents a life-threatening condition requiring thymus transplantation. The majority of patients have partial DiGeorge syndrome with variable degrees of T-cell dysfunction that often improves with age through spontaneous immune reconstitution. Implementation of TREC-based newborn screening has revolutionized early detection, enabling earlier diagnosis and intervention.[6]

Approximately 90% of DiGeorge syndrome cases result from a microdeletion on the long arm of chromosome 22 at the 11.2 locus, typically involving a 3-megabase region between low copy repeats LCR22A and LCR22D (see Image. DiGeorge Syndrome Karyotype).[7] This common deletion encompasses approximately 90 genes, creating haploinsufficiency for multiple genes critical for normal development. The majority of deletions occur de novo, arising as new mutations during meiosis without parental inheritance.[8] However, 6% to 10% of cases represent inherited deletions from a parent with 22q11.2 deletion syndrome who may have mild or atypical features that went unrecognized. When a parent carries the deletion, offspring have a 50% chance of inheriting the abnormality, following an autosomal dominant inheritance pattern.[2][9] Among the genes within the deleted region, TBX1 (T-box transcription factor 1) has emerged as the most extensively studied and clinically relevant candidate gene. TBX1 haploinsufficiency correlates with the severity of cardiac, thymic, and parathyroid defects in both mouse models and humans. The gene plays a critical role in pharyngeal arch development, and its deletion results in abnormal migration and differentiation of neural crest cells, leading to the characteristic constellation of cardiac conotruncal malformations, thymic hypoplasia, parathyroid hypoplasia, and craniofacial abnormalities.[10] Other genes within the region contribute to specific phenotypic features. The COMT gene, which metabolizes dopamine and other catecholamines, has been implicated in the elevated risk of psychiatric disorders and cognitive dysfunction.[11] The PRODH gene encodes proline dehydrogenase, and its deletion may contribute to both psychiatric manifestations and immune dysregulation.[12] Nondeletion causes of DiGeorge syndrome phenotype include mutations in TBX1, CHARGE syndrome due to CHD7 mutations, maternal diabetes (diabetic embryopathy), fetal alcohol syndrome, and retinoic acid embryopathy.[13] These non-22q11.2 deletion etiologies account for approximately 10% of cases of DiGeorge syndrome and warrant consideration when genetic testing for a 22q11.2 deletion is negative despite classic clinical features.

The 22q11.2 deletion represents the most common microdeletion syndrome in humans, with an estimated prevalence of approximately 1 in 2,000 to 1 in 4,000 live births.[9] Recent population-based newborn screening studies using TREC assays have refined prevalence estimates, with one large study reporting a birth prevalence of 1 in 2,148. The incidence appears to be increasing over time due to improved detection through TREC-based newborn screening programs and enhanced clinical recognition, as well as to the reproductive success of affected individuals, who transmit the deletion to their offspring.[6] Prenatal prevalence of 22q11.2 deletion is significantly higher than in live births, with studies estimating fetal prevalence at approximately 1 in 1,000.[14] The discrepancy between fetal and live birth prevalence suggests substantial prenatal and early neonatal mortality, likely due to severe cardiac malformations and other life-threatening congenital anomalies. DiGeorge syndrome affects males and females equally without sex predilection.[15] Geographic and ethnic variations in diagnosis rates have been documented, though these likely reflect ascertainment bias and healthcare access disparities rather than true differences in prevalence. African-American children with 22q11.2 deletion may not manifest the classic craniofacial dysmorphism characteristic in other ethnic groups, contributing to underdiagnosis in this population.[8] Complete DiGeorge syndrome affects fewer than 1% of individuals with 22q11.2 deletion. However, this severe phenotype accounts for a disproportionate share of morbidity and mortality in infancy without thymus transplantation.[16] The syndrome remains significantly underdiagnosed, particularly in adults presenting with isolated psychiatric symptoms or mild phenotypic features.[17]

The pathophysiology of DiGeorge syndrome stems from haploinsufficiency of genes within the 22q11.2 region, with TBX1 playing the central role in most characteristic features. During early embryogenesis, TBX1 is expressed in the pharyngeal apparatus and surrounding mesenchyme, where it regulates the development of structures derived from the third and fourth pharyngeal pouches and arches.[18] Cardiac abnormalities result from abnormal migration and differentiation of cardiac neural crest cells, which normally contribute to the formation of the cardiac outflow tract and aortic arch. TBX1 haploinsufficiency disrupts this process, leading to conotruncal malformations including tetralogy of Fallot, truncus arteriosus, interrupted aortic arch, ventricular septal defects, and aortic arch anomalies.[19] The right aortic arch, though not always causing hemodynamic compromise, occurs in approximately 20% of individuals with 22q11.2 deletion. Thymic hypoplasia or aplasia results from failed development of the thymic anlage from the third pharyngeal pouch. The degree of thymic deficiency determines the severity of T-cell immunodeficiency. In partial DiGeorge syndrome, residual thymic tissue produces T cells, albeit in reduced numbers, with many patients experiencing gradual improvement in T-cell counts through compensatory proliferation of existing T cells. Complete DiGeorge syndrome represents complete failure of thymic development, resulting in profound T-cell lymphopenia with fewer than 50 naive T cells per microliter and absent thymic output. Without thymic tissue to support T-cell maturation, infants with complete DiGeorge syndrome develop severe combined immunodeficiency-like phenotype with life-threatening infections.[5][20] Recent research has elucidated that thymic hypoplasia leads to homeostatic proliferation of existing T cells to maintain peripheral T-cell numbers. This compensatory mechanism results in a restricted T-cell receptor repertoire, altered CD4:CD8 ratios, and skewing toward a Th2-dominant immune phenotype. The altered T-cell homeostasis contributes to both increased susceptibility to infections and elevated risk of autoimmune disorders.[20]

Recent research has elucidated that thymic hypoplasia leads to homeostatic proliferation of existing T cells to maintain peripheral T-cell numbers. This compensatory mechanism results in a restricted T-cell receptor repertoire, altered CD4:CD8 ratios, and skewing toward a Th2-dominant immune phenotype. The altered T-cell homeostasis contributes to both increased susceptibility to infections and elevated risk of autoimmune disorders.[20] Parathyroid hypoplasia results from abnormal development of the parathyroid glands, which originate from the third and fourth pharyngeal pouches. The resulting hypoparathyroidism manifests as hypocalcemia of variable severity, ranging from neonatal seizures and tetany to subclinical hypocalcemia detected only with biochemical screening.[21] The elevated risk of psychiatric disorders, particularly schizophrenia spectrum disorders, involves multiple mechanisms. Haploinsufficiency of COMT leads to reduced degradation of dopamine in the prefrontal cortex, potentially contributing to altered dopaminergic neurotransmission.[11] Recent studies have identified microvascular abnormalities and altered mitochondrial function in neural development, potentially explaining the structural brain differences and cognitive trajectories observed in 22q11.2 deletion syndrome. The paradoxical occurrence of autoimmunity in a syndrome characterized by immunodeficiency relates to defective thymic selection processes. Reduced thymic output and altered thymic epithelial cell function may impair central tolerance mechanisms, allowing autoreactive T cells to escape into the periphery.[20]

A comprehensive history and physical examination are essential for diagnosing and assessing DiGeorge syndrome. Given the broad spectrum of disease severity and variable phenotypic expression, a high index of suspicion is warranted in patients presenting with suggestive features.[2][8][21] Clinical History The prenatal and birth history may reveal prenatal ultrasound findings suggestive of cardiac anomalies, polyhydramnios, or thymic hypoplasia. A history of positive TREC newborn screen indicating T-cell lymphopenia provides an essential early diagnostic clue.[6] Neonatal hypocalcemia presenting with jitteriness, tremors, or seizures is common. The developmental and educational history often reveals delayed motor milestones, speech and language delays, particularly affecting articulation, and learning disabilities affecting mathematics, reading comprehension, and abstract reasoning. Many children require special education services or developmental interventions.[4] The infectious history may demonstrate recurrent sinopulmonary infections, including otitis media, sinusitis, and pneumonia. In severely immunocompromised patients, severe or opportunistic infections may occur, along with unusual susceptibility to viral infections.[5] Medical complications include episodes of hypocalcemia with tetany, paresthesias, or carpopedal spasm, seizure disorders, particularly in infancy, feeding difficulties, failure to thrive, and gastroesophageal reflux.[21] Chronic constipation or other gastrointestinal complaints are common.[2] Psychiatric and behavioral history reveals a developmental trajectory of symptoms with anxiety disorders, particularly social anxiety and specific phobias common in childhood, attention-deficit/hyperactivity disorder symptoms, and autism spectrum disorder features. In adolescence and adulthood, psychotic symptoms, mood disorders, and schizophrenia may emerge.[22] Family history may reveal a known 22q11.2 deletion in a parent or sibling, family history of congenital heart disease, learning disabilities, or psychiatric disorders, or unexplained neonatal or infant deaths representing potential undiagnosed cases.[2] Physical Examination Findings

Psychiatric and behavioral history reveals a developmental trajectory of symptoms with anxiety disorders, particularly social anxiety and specific phobias common in childhood, attention-deficit/hyperactivity disorder symptoms, and autism spectrum disorder features. In adolescence and adulthood, psychotic symptoms, mood disorders, and schizophrenia may emerge.[22] Family history may reveal a known 22q11.2 deletion in a parent or sibling, family history of congenital heart disease, learning disabilities, or psychiatric disorders, or unexplained neonatal or infant deaths representing potential undiagnosed cases.[2] Physical Examination Findings Physical examination reveals characteristic craniofacial features present in approximately 70% of patients, though their expression varies. These include an elongated face with almond-shaped palpebral fissures, a bulbous nasal tip with narrow nasal passages, malar flattening representing underdeveloped cheekbones, micrognathia or retrognathia, low-set or posteriorly rotated ears with abnormal helices, hypertelorism, a short philtrum, and a thin upper lip (see Image. DiGeorge Syndrome). Oropharyngeal examination may reveal overt cleft palate or submucous cleft palate, bifid uvula, velopharyngeal insufficiency detected by hypernasal speech, and small tonsils reflecting thymic-dependent lymphoid tissue hypoplasia.[2][8] Cardiovascular examination demonstrates cardiac murmurs suggesting structural heart disease, cyanosis indicating conotruncal defects, signs of heart failure in severe cases, and diminished or absent femoral pulses in cases of interrupted aortic arch.[23] Musculoskeletal examination shows hypotonia, particularly in infancy, slender tapered fingers, and occasionally scoliosis or vertebral anomalies. Neurological examination reveals developmental delays across multiple domains, abnormal muscle tone, and signs of hypocalcemia, including the Chvostek and Trousseau signs. Growth parameters may show short stature in approximately 35% of patients and failure to thrive in infancy. The physical examination findings vary significantly among individuals, with some having obvious dysmorphic features while others appear phenotypically normal. Absence of characteristic facial features does not exclude the diagnosis, particularly in specific ethnic populations.[2][9]

A definitive diagnosis of DiGeorge syndrome requires confirmation of a 22q11.2 deletion through genetic testing. However, a clinical diagnosis may be established when the characteristic phenotype is present in the absence of an identifiable genetic etiology. Chromosomal microarray analysis represents the current gold standard for detecting 22q11.2 deletions.[21] This technique identifies deletions and duplications across the genome with high resolution and can detect atypical or smaller deletions within 22q11.2 that may be missed by fluorescence in situ hybridization. Chromosomal microarray is recommended as the first-tier test for patients with suggestive clinical features.[9] Immunological evaluation is critical for all patients at diagnosis. Complete blood count with differential assesses absolute lymphocyte count, which may reveal lymphopenia but can be normal in partial DiGeorge syndrome. Lymphocyte subset analysis by flow cytometry quantifies absolute counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD16+/CD56+ natural killer cells. This testing is most critical for determining whether a phenotype is complete or partial. T-cell maturation markers, including CD45RA+ naive T cells and recent thymic emigrants, provide important prognostic information.[20] T-cell receptor excision circles (TREC) quantify recent thymic emigrants and are low or absent in complete DiGeorge syndrome. This biomarker is identified through newborn screening in many cases and proves useful for longitudinal monitoring. Lymphocyte proliferation assays assess response to mitogens, eg, phytohemagglutinin.[6] Complete DiGeorge syndrome demonstrates less than 20-fold proliferation, while partial DiGeorge syndrome shows variable responses.[24] Immunoglobulin levels should be quantified, as many patients develop humoral immunodeficiency over time.[21]

T-cell receptor excision circles (TREC) quantify recent thymic emigrants and are low or absent in complete DiGeorge syndrome. This biomarker is identified through newborn screening in many cases and proves useful for longitudinal monitoring. Lymphocyte proliferation assays assess response to mitogens, eg, phytohemagglutinin.[6] Complete DiGeorge syndrome demonstrates less than 20-fold proliferation, while partial DiGeorge syndrome shows variable responses.[24] Immunoglobulin levels should be quantified, as many patients develop humoral immunodeficiency over time.[21] Cardiovascular evaluation includes echocardiography in all newly diagnosed patients to evaluate for conotruncal defects, septal defects, and aortic arch anomalies.[15] An endocrine evaluation assesses calcium homeostasis using serum ionized calcium or corrected total calcium, serum phosphorus, magnesium, and intact parathyroid hormone. These parameters should be checked at diagnosis and periodically thereafter, as hypocalcemia can present at any age. Thyroid function tests screen for autoimmune thyroid disease, which affects 10% to 22% of patients.[21] Additional evaluations in patients with DiGeorge syndrome include: Renal ultrasound to assess for structural renal anomalies occurring in 30% to 35% of patients Audiological evaluation for hearing loss Ophthalmological examination Gastrointestinal assessment Developmental and neuropsychological assessment Psychiatric screening beginning in adolescence using validated tools, eg, the Structured Interview for Psychosis-Risk Syndromes [21][22] Table Pause and Reflect A 3-month-old male infant presents to the immunology clinic following an abnormal TREC result on newborn screening. The infant was born at 39 weeks via an uncomplicated vaginal delivery. At age 2 weeks, he was hospitalized for neonatal (more...)

Management of DiGeorge syndrome requires comprehensive, lifelong, interprofessional care tailored to each individual's specific manifestations and severity.[9][21][25] For patients with partial DiGeorge syndrome, infection prevention includes antibiotic prophylaxis for recurrent sinopulmonary infections and trimethoprim-sulfamethoxazole for Pneumocystis jirovecii prophylaxis in severely T-cell lymphopenic infants. Immunoglobulin replacement therapy with intravenous or subcutaneous immunoglobulin is indicated for patients with hypogammaglobulinemia and recurrent infections, with typical dosing of 400 to 600 mg/kg every 3 to 4 weeks and trough IgG levels monitored, targeting greater than 500 to 600 mg/dL.[5] Vaccination Considerations Vaccination considerations require careful assessment. Inactivated vaccines are safe and recommended per the standard schedule. Live attenuated vaccines, including measles-mumps-rubella and varicella, require careful assessment, with current guidelines recommending live vaccines in children older than 12 months who have CD4+ T cells greater than 500 cells per microliter, CD8+ T cells greater than 300 cells per µL, and documented vaccine responses to inactivated vaccines. The rotavirus vaccine is contraindicated in infants with severe T-cell lymphopenia because of the risk of prolonged shedding. T-cell counts should be reassessed before each live vaccine administration. Longitudinal immunological monitoring includes T-cell subsets every 6 to 12 months during childhood, immunoglobulin levels annually, and vaccine titers to assess humoral immunity.[9][21] Complete DiGeorge Syndrome

Vaccination considerations require careful assessment. Inactivated vaccines are safe and recommended per the standard schedule. Live attenuated vaccines, including measles-mumps-rubella and varicella, require careful assessment, with current guidelines recommending live vaccines in children older than 12 months who have CD4+ T cells greater than 500 cells per microliter, CD8+ T cells greater than 300 cells per µL, and documented vaccine responses to inactivated vaccines. The rotavirus vaccine is contraindicated in infants with severe T-cell lymphopenia because of the risk of prolonged shedding. T-cell counts should be reassessed before each live vaccine administration. Longitudinal immunological monitoring includes T-cell subsets every 6 to 12 months during childhood, immunoglobulin levels annually, and vaccine titers to assess humoral immunity.[9][21] Complete DiGeorge Syndrome For patients with complete DiGeorge syndrome, immediate management requires strict reverse isolation to prevent infections, irradiated leukocyte-reduced CMV-negative blood products only, no live attenuated vaccines, prophylactic antimicrobials including antibacterial, antifungal, and antiviral agents, IVIG replacement therapy, and aggressive treatment of infections. Definitive treatment involves thymus transplantation using FDA-approved cultured postnatal thymus tissue. Allogeneic thymus tissue obtained from infants undergoing cardiac surgery is cultured to expand thymic epithelial cells and remove donor T cells, then implanted into the quadriceps muscle under general anesthesia. Importantly, this procedure does not require HLA matching between donor and recipient.[5][16] Thymus transplantation outcomes demonstrate overall survival of 73% to 75% in multicenter studies.[16][26] Naive T-cell development begins 3 to 5 months posttransplantation, with a diverse T-cell receptor repertoire developing by 12 months. Most survivors discontinue prophylactic antibiotics and IVIG within the first year. Immunosuppression, if used, is typically discontinued once naive T cells appear. The most common complication involves autoimmune disorders, particularly autoimmune thyroiditis occurring in 10% to 15% of recipients, along with immune cytopenias and, less commonly, autoimmune enteropathy, hepatitis, or nephrotic syndrome.

Thymus transplantation outcomes demonstrate overall survival of 73% to 75% in multicenter studies.[16][26] Naive T-cell development begins 3 to 5 months posttransplantation, with a diverse T-cell receptor repertoire developing by 12 months. Most survivors discontinue prophylactic antibiotics and IVIG within the first year. Immunosuppression, if used, is typically discontinued once naive T cells appear. The most common complication involves autoimmune disorders, particularly autoimmune thyroiditis occurring in 10% to 15% of recipients, along with immune cytopenias and, less commonly, autoimmune enteropathy, hepatitis, or nephrotic syndrome. Cardiac management includes cardiology evaluation at diagnosis and regular follow-up, surgical repair of conotruncal defects typically in infancy with special precautions during cardiac surgery for immunodeficient patients, including use of irradiated leukocyte-reduced CMV-negative blood products, endocarditis prophylaxis per current guidelines, and lifelong cardiology follow-up for residual lesions and late complications.[15] Endocrine management of hypoparathyroidism and hypocalcemia involves calcium supplementation with elemental calcium 30 to 75 mg/kg/day, divided 3 to 4 times daily, and active vitamin D calcitriol 0.25 to 2 µg/day. Serum calcium, phosphorus, magnesium, and calcium:creatinine ratio require monitoring, targeting a serum calcium within the low-normal range to avoid hypercalciuria. Recombinant human PTH may be considered for refractory cases. Thyroid disorders require annual TSH and free T4 screening with levothyroxine replacement for hypothyroidism and antithyroid medications or radioablation for hyperthyroidism, noting that hypocalcemia can worsen after thyroid ablation.[9][21] Surgical and otolaryngological management addresses cleft palate and velopharyngeal insufficiency through surgical repair of cleft palate typically between 9 and 18 months of age and pharyngoplasty for velopharyngeal insufficiency, with speech therapy pre- and post-operatively. Tympanostomy tube placement treats recurrent otitis media and effusions with regular audiological monitoring.[27][28][29] Supportive Therapies

Surgical and otolaryngological management addresses cleft palate and velopharyngeal insufficiency through surgical repair of cleft palate typically between 9 and 18 months of age and pharyngoplasty for velopharyngeal insufficiency, with speech therapy pre- and post-operatively. Tympanostomy tube placement treats recurrent otitis media and effusions with regular audiological monitoring.[27][28][29] Supportive Therapies Developmental and educational support includes early intervention services from birth to 3 years, special education services with individualized education plans, speech and language therapy for articulation and language delays, occupational therapy for fine motor delays and sensory processing difficulties, physical therapy for gross motor delays and hypotonia, educational modifications for learning disabilities, and transition planning for adolescents moving to adulthood.[30] Psychiatric management in childhood involves early screening and treatment for attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders, autism spectrum disorder interventions when indicated, cognitive behavioral therapy for anxiety, selective serotonin reuptake inhibitors for anxiety disorders, and stimulant or nonstimulant medications for ADHD with careful monitoring. In adolescence and adulthood, structured assessment for prodromal psychotic symptoms beginning at age 12 to 14 years enables early intervention for at-risk mental states.[22] Schizophrenia spectrum disorders develop in 25% to 30% of adults, requiring antipsychotic medications with lower starting doses recommended due to increased sensitivity and monitoring for metabolic side effects. Mood stabilizers treat bipolar disorder, while depression responds to SSRIs/SNRIs and psychotherapy. An interprofessional mental health team, including psychiatry, psychology, and social work, optimizes outcomes.[4] Genetic counseling provides comprehensive education at diagnosis explaining 22q11.2 deletion syndrome as a genetic condition, discussion of de novo versus inherited deletion with importance of parental testing, 50% recurrence risk when inherited from affected parent, prenatal testing options including chorionic villus sampling and amniocentesis, preimplantation genetic diagnosis availability for at-risk couples, and cascade testing of parents and siblings.[9][21]

Many clinical features of DiGeorge syndrome (22q11.2 deletion syndrome) overlap with other congenital and genetic disorders. Therefore, establishing the correct diagnosis requires comprehensive clinical assessment and genetic consultation. The following conditions may present with overlapping findings: Smith-Lemli-Opitz syndrome: Characterized by defects in cholesterol biosynthesis (DHCR7 mutations). Common features include cardiac anomalies, cleft palate, and developmental delays, with distinguishing findings, eg, 2-toe or 3-toe syndactyly and low serum cholesterol levels.[31] Oculo-auriculo-vertebral spectrum (Goldenhar syndrome): Presents with hemifacial microsomia, ear anomalies, vertebral and cardiac defects, and typically asymmetric facial features. Most cases are sporadic.[32] Alagille syndrome: Caused by JAG1 or NOTCH2 mutations. Overlapping features include congenital heart disease, butterfly vertebrae, and posterior embryotoxon, whereas cholestatic liver disease is distinctive.[33] VATER/VACTERL association: Involves vertebral anomalies, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb malformations. This condition lacks immunodeficiency or hypocalcemia and remains a diagnosis of exclusion with no established genetic etiology.[34] CHARGE syndrome: Due to CHD7 mutations, shares multiple features with DiGeorge syndrome, including congenital heart disease, choanal atresia, coloboma, renal anomalies, growth deficiency, and ear/hearing abnormalities. Thymic hypoplasia and T-cell lymphopenia are seen in 20% to 30% of cases.[35] Other forms of severe combined immunodeficiency (SCID): Resulting from IL2RG, RAG1/RAG2, ADA, JAK3, or IL7R mutations, these disorders cause profound T-cell (and often B/NK-cell) deficiencies but lack the cardiac and craniofacial features characteristic of DiGeorge syndrome.[36] Ataxia-telangiectasia: Due to ATM mutations, this condition presents with progressive cerebellar ataxia, oculocutaneous telangiectasias, T-cell lymphopenia, and elevated alpha-fetoprotein, distinguishing it by its neurological manifestations.[37] Hypoparathyroidism-deafness-renal dysplasia syndrome: Caused by GATA3 mutations, presents with hypoparathyroidism, sensorineural hearing loss, and renal anomalies without cardiac or immunologic abnormalities.[38]

Ataxia-telangiectasia: Due to ATM mutations, this condition presents with progressive cerebellar ataxia, oculocutaneous telangiectasias, T-cell lymphopenia, and elevated alpha-fetoprotein, distinguishing it by its neurological manifestations.[37] Hypoparathyroidism-deafness-renal dysplasia syndrome: Caused by GATA3 mutations, presents with hypoparathyroidism, sensorineural hearing loss, and renal anomalies without cardiac or immunologic abnormalities.[38] Autoimmune polyendocrine syndrome type 1: Related to AIRE mutations, features hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis, often with multiple autoimmune endocrinopathies emerging sequentially.[39] Stickler syndrome: Associated with COL2A1 and other collagen gene mutations. Presents with cleft palate, high myopia, vitreoretinal degeneration, and hearing loss, but lacks cardiac or immune dysfunction.[40] Fetal alcohol syndrome: Characterized by similar facial dysmorphism, cardiac defects, and developmental delays, with a maternal history of alcohol exposure.[41] Because features of DiGeorge syndrome can appear as isolated anomalies in otherwise healthy individuals, genetic consultation and correlation with the complete clinical picture are essential for an accurate diagnosis.

The prognosis of DiGeorge syndrome varies dramatically based on the severity of initial manifestations, particularly the degree of cardiac and immunological involvement. Complete DiGeorge syndrome without thymus transplantation is uniformly fatal by 12 to 24 months of age due to severe infections. With thymus transplantation, survival rates of 73% to 75% for 2 years and beyond have been achieved in recent multicenter studies. Even with successful transplantation, survivors face elevated morbidity from autoimmune complications and require lifelong monitoring.[2][9][16][21] Partial DiGeorge syndrome demonstrates a highly variable prognosis dependent on individual manifestations. Infant mortality historically reached 4% to 8% due to critical congenital heart disease, but improved cardiac surgical outcomes have substantially reduced early mortality. Studies indicate premature mortality in adults with 22q11.2 deletion syndrome, with a median age of death of approximately 40 to 45 years, representing approximately 20 to 25 years earlier than the general population.[14] Leading causes of death in adults include cardiovascular complications from residual or progressive cardiac disease, sudden cardiac death, psychiatric causes including suicide, and aspiration pneumonia related to velopharyngeal dysfunction and gastroesophageal reflux.[42] Most require special education support or academic accommodations, though some individuals achieve higher education and professional success. Employment rates remain lower than those of the general population, at approximately 20% to 40% in competitive employment, with many requiring supported employment or vocational rehabilitation services. Approximately 30% to 50% of adults achieve independent living.[17] Factors associated with better prognosis include absence of severe cardiac defects or successful early cardiac repair, partial rather than complete DiGeorge syndrome, normal or mildly decreased T-cell function with preserved vaccine responses, absence of severe neurodevelopmental delays, early diagnosis enabling anticipatory guidance and preventive interventions, access to comprehensive interprofessional care, higher socioeconomic status and family support, and absence of psychiatric comorbidities.

Factors associated with better prognosis include absence of severe cardiac defects or successful early cardiac repair, partial rather than complete DiGeorge syndrome, normal or mildly decreased T-cell function with preserved vaccine responses, absence of severe neurodevelopmental delays, early diagnosis enabling anticipatory guidance and preventive interventions, access to comprehensive interprofessional care, higher socioeconomic status and family support, and absence of psychiatric comorbidities. Contemporary improvements in prognosis result from TREC-based newborn screening enabling earlier diagnosis and intervention, FDA-approved thymus transplantation for complete DiGeorge syndrome, advanced cardiac surgical techniques and perioperative management, improved understanding of psychiatric trajectories and early intervention strategies, updated clinical practice guidelines facilitating comprehensive care, specialized interprofessional 22q11.2 deletion syndrome clinics, and patient advocacy organizations providing education and support.[6]

Several complications are associated with DiGeorge syndrome; therefore, consistent follow-up of patients with DiGeorge syndrome is essential to evaluate for possible sequelae, eg, severe recurrent infections, autoimmune diseases, and hematologic malignancies (see Table. Complications Associated With DiGeorge Syndrome). Table Table. Complications Associated With DiGeorge Syndrome.

Comprehensive patient and family education is essential for optimizing outcomes in DiGeorge syndrome.[9] Genetic counseling should explain the 22q11.2 deletion as a genetic condition, differentiate de novo from inherited deletions, and emphasize parental testing. Families should understand the 50% recurrence risk when inherited, options for prenatal or preimplantation genetic diagnosis, and variable expressivity within affected relatives. Cascade testing for siblings and extended family is also recommended. Additionally, for affected adults, counseling focuses on reproductive risks, prenatal diagnostic options, fetal cardiac evaluation, and management considerations during pregnancy. Alternatives, eg, adoption or gamete donation, should be discussed. Infection prevention education includes strict hand hygiene, avoiding exposure to ill contacts, prompt evaluation for fever, adherence to prophylactic antibiotics or IVIG, and ensuring family vaccination—especially annual influenza immunization. Patients and caregivers should also be instructed on the symptoms of hypocalcemia. Hypocalcemia education teaches early recognition of symptoms, eg, cramps, tingling, spasms, seizures, and cardiac symptoms, and to maintain adherence to calcium and vitamin D supplementation. Parents should understand appropriate dosing, the need for regular labs, and when to seek emergency care. Psychiatric education prepares families to identify early symptoms of psychosis, eg, social withdrawal, academic decline, or paranoia. Ongoing psychiatric monitoring, early intervention, medication adherence, and destigmatization of mental health care are emphasized. Adolescents and adults should learn self-awareness, substance use risks, and crisis planning.

DiGeorge syndrome is a complex multisystem disorder that requires a high index of suspicion and comprehensive interprofessional evaluation. The following mnemonic, “CATCH-22,” can aid clinicians in remembering key factors to evaluate: Conotruncal cardiac anomalies Abnormal facies Thymic hypoplasia Cleft palate Hypocalcemia 22q11.2 microdeletion

DiGeorge syndrome exemplifies a disorder that demands comprehensive interprofessional collaboration for optimal outcomes. The multisystem nature, variable expressivity, and evolving manifestations across the lifespan require coordination among primary care clinicians, geneticists, immunologists, cardiologists, endocrinologists, psychiatrists, and allied health professionals. Primary care serves as the medical home overseeing surveillance, growth and development, vaccinations, and timely specialty referral while geneticists and genetic counselors confirm the diagnosis, provide recurrence risk counseling, and guide family testing and reproductive planning. Immunologists, cardiologists, endocrinologists, otolaryngologists, and psychiatrists play central roles in managing key organ-specific complications. Immunologists tailor vaccination schedules, prescribe prophylaxis, and monitor immune function. Cardiologists and surgeons repair congenital defects and monitor late complications. Endocrinologists manage hypocalcemia, thyroid disease, and metabolic issues. Psychiatrists and psychologists screen for early psychiatric symptoms, provide therapy, and manage psychosis risk. Speech-language pathologists, nutritionists, and developmental specialists support communication, feeding, and learning needs. Effective interprofessional care involves regular interprofessional meetings, shared electronic records, and coordinated transition planning from pediatric to adult care. Patient and family engagement through shared decision-making and education fosters adherence and self-advocacy. Specialized 22q11.2 deletion syndrome clinics and telemedicine services improve access, care continuity, and family support. Ultimately, collaboration across specialties enhances early detection, comprehensive management, quality of life, and long-term outcomes for individuals with DiGeorge syndrome.